264 related articles for article (PubMed ID: 34762717)
21. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.
Campos C; López N; Pera A; Gordillo JJ; Hassouneh F; Tarazona R; Solana R
Biogerontology; 2015 Oct; 16(5):671-83. PubMed ID: 25991472
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cell phenotype is altered in HIV-exposed seronegative women.
Zhao NQ; Vendrame E; Ferreira AM; Seiler C; Ranganath T; Alary M; Labbé AC; Guédou F; Poudrier J; Holmes S; Roger M; Blish CA
PLoS One; 2020; 15(9):e0238347. PubMed ID: 32870938
[TBL] [Abstract][Full Text] [Related]
23. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection.
Brunetta E; Fogli M; Varchetta S; Bozzo L; Hudspeth KL; Marcenaro E; Moretta A; Mavilio D
AIDS; 2010 Jan; 24(1):27-34. PubMed ID: 19910789
[TBL] [Abstract][Full Text] [Related]
24. Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.
Fogli M; Mavilio D; Brunetta E; Varchetta S; Ata K; Roby G; Kovacs C; Follmann D; Pende D; Ward J; Barker E; Marcenaro E; Moretta A; Fauci AS
PLoS Pathog; 2008 Jul; 4(7):e1000101. PubMed ID: 18617991
[TBL] [Abstract][Full Text] [Related]
25. Persistence of pathological distribution of NK cells in HIV-infected patients with prolonged use of HAART and a sustained immune response.
Frias M; Rivero-Juarez A; Gordon A; Camacho A; Cantisan S; Cuenca-Lopez F; Torre-Cisneros J; Peña J; Rivero A
PLoS One; 2015; 10(3):e0121019. PubMed ID: 25811634
[TBL] [Abstract][Full Text] [Related]
26. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M
Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002
[TBL] [Abstract][Full Text] [Related]
27. Immune Dysfunctions of CD56
Cao WJ; Zhang XC; Wan LY; Li QY; Mu XY; Guo AL; Zhou MJ; Shen LL; Zhang C; Fan X; Jiao YM; Xu RN; Zhou CB; Yuan JH; Wang SQ; Wang FS; Song JW
Front Immunol; 2021; 12():811091. PubMed ID: 35069597
[TBL] [Abstract][Full Text] [Related]
28. B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape.
Lucar O; Sadjo Diallo M; Bayard C; Samri A; Tarantino N; Debré P; Thiébaut R; Brun-Vézinet F; Matheron S; Cheynier R; Vieillard V;
AIDS; 2019 Jan; 33(1):23-32. PubMed ID: 30325780
[TBL] [Abstract][Full Text] [Related]
29. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment.
Bozzano F; Picciotto A; Costa P; Marras F; Fazio V; Hirsch I; Olive D; Moretta L; De Maria A
Eur J Immunol; 2011 Oct; 41(10):2905-14. PubMed ID: 21695691
[TBL] [Abstract][Full Text] [Related]
30. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection.
Varchetta S; Mele D; Lombardi A; Oliviero B; Mantovani S; Tinelli C; Spreafico M; Prati D; Ludovisi S; Ferraioli G; Filice C; Aghemo A; Lampertico P; Facchetti F; Bernuzzi F; Invernizzi P; Mondelli MU
Gut; 2016 Dec; 65(12):1998-2006. PubMed ID: 26674359
[TBL] [Abstract][Full Text] [Related]
31. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.
Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
Blood Adv; 2022 Jun; 6(11):3352-3366. PubMed ID: 35294519
[TBL] [Abstract][Full Text] [Related]
32. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
33. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients.
Johansson SE; Rollman E; Chung AW; Center RJ; Hejdeman B; Stratov I; Hinkula J; Wahren B; Kärre K; Kent SJ; Berg L
Viral Immunol; 2011 Oct; 24(5):359-68. PubMed ID: 21958370
[TBL] [Abstract][Full Text] [Related]
34. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
35. Modulation of expression of the MHC class I-binding natural killer cell receptors, and NK activity in relation to viral load in HIV-infected/AIDS patients.
Ahmad R; Sindhu ST; Tran P; Toma E; Morisset R; Menezes J; Ahmad A
J Med Virol; 2001 Nov; 65(3):431-40. PubMed ID: 11596074
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the Characteristics of TIGIT-Expressing CD3
Zhang X; Lu X; Cheung AKL; Zhang Q; Liu Z; Li Z; Yuan L; Wang R; Liu Y; Tang B; Xia H; Wu H; Zhang T; Su B
Front Immunol; 2021; 12():602492. PubMed ID: 33717085
[TBL] [Abstract][Full Text] [Related]
37. Polyfunctional natural killer cells with a low activation profile in response to Toll-like receptor 3 activation in HIV-1-exposed seronegative subjects.
Lima JF; Oliveira LMS; Pereira NZ; Duarte AJS; Sato MN
Sci Rep; 2017 Apr; 7(1):524. PubMed ID: 28373665
[TBL] [Abstract][Full Text] [Related]
38. [Reduced frequency of natural killer cell on siglec-7(+) is associated with progression of hepatitis B virus-related cirrhosis].
Li YL; Zhang QF; Yin WW; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2018 Jun; 26(6):420-425. PubMed ID: 30317754
[No Abstract] [Full Text] [Related]
39. Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset.
Mantegani P; Tambussi G; Galli L; Din CT; Lazzarin A; Fortis C
Immunology; 2010 Feb; 129(2):220-33. PubMed ID: 19824914
[TBL] [Abstract][Full Text] [Related]
40. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.
Xiao R; Tian Y; Zhang J; Li N; Qi M; Liu L; Wang J; Li Z; Zhang J; Zhao F; Wang T; Tan S; Li C; Wu Z; Yu M; Jiang X; Zhan P; Gao L; Han B; Liu X; Liang X; Ma C
J Hepatol; 2024 May; 80(5):792-804. PubMed ID: 38331327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
